Nemaura Medical, Inc. operates as a holding company. The company is headquartered in Manhattan, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.
最新の財務諸表(Form-10K)によると、Nemaura Medical Incの総資産は$14で、純損失は$-14です。
NMRDの主要な財務比率は何ですか?
Nemaura Medical Incの流動比率は0.53、純利益率は0、1株当たり売上高は$0です。
Nemaura Medical Incの収益はセグメントまたは地域別にどのように分けられていますか?
Nemaura Medical Inc の最大収益セグメントは Technology and Data Processing Fees で、最新の利益発表における収益は 80,083,582 です。地域別に見ると、Europe が Nemaura Medical Inc の主要市場であり、収益は 47,504,482 です。